What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least three kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

ABECMA may be an option
even earlier in your treatment plan

ABECMA may be a treatment option when multiple myeloma has come back (relapsed) or stopped responding to treatment (refractory) after you have received at least 2 kinds of treatment regimens that include a therapy from each of 3 drug classes.

This includes at least 1 from each of the 3 drug classes below:

  • Immunomodulatory Agent
    • Lenalidomide
    • Pomalidomide
  • Proteasome Inhibitor
    • Bortezomib
    • Carfilzomib
    • Ixazomib
  • Anti-CD38 Monoclonal Antibody
    • Daratumumab
    • Isatuximab-irfc

You may have been given a combination of these drug types at one time.

Please see product safety information at the respective websites for agents listed above.

Focus on your freedom after receiving ABECMA

While regular check-ins with your healthcare team are still required, the following are NOT required for your multiple myeloma while responding to ABECMA:

An infusion bag crossed out indicating repeated infusions are not required

A calendar crossed out indicating maintenance therapy is not required

A pill bottle crossed out indicating daily pills are not required

Start the conversation
with your doctor:

Your doctor will consider clinical factors such as age and overall health
when deciding if ABECMA is right for you.

download the abecma eligibility guide Descargar en Español

ABECMA is different from
a stem cell transplant

You may have heard of or even had a stem cell transplant, which has a different treatment process from ABECMA. ABECMA may be an option even if a stem cell transplant is not.

  • ABECMA uses customized cells, where your T cells are modified to work just for you
  • A short course of chemotherapy is required before your ABECMA treatment
  • The initial monitoring period for ABECMA lasts at least 7 days at the treatment center
  • No maintenance therapy for the multiple myeloma is required after ABECMA, as long as you are responding to treatment*

*Regular check-ins with your healthcare team are still needed.

See how people responded to
ABECMA in clinical studies

see results

Find a certified treatment
center near you

find a location